Nedaplatin

Summary

Nedaplatin (CHEMBL3137685) is a phase-3 clinical-stage small molecule; indicated across 10 conditions including carcinoma of esophagus and non-small cell lung carcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 10 conditions
• Clinical trials: 42

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3137685
Name	Nedaplatin
Type	Small molecule
Max phase	3

Also known as: Aqupla, Cis-diammine-glycolatoplatinum, Nedaplatin, Nedaplatine, Nedaplatino, NSC-375101D, NEDAPLATINE, NEDAPLATIN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

10 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
carcinoma of esophagus	3	MONDO:0019086	EFO:0002916
non-small cell lung carcinoma	3	MONDO:0005233	EFO:0003060
esophageal squamous cell carcinoma	3	MONDO:0005580	EFO:0005922
squamous cell carcinoma	3	MONDO:0005096	EFO:0000707
head and neck squamous cell carcinoma	3	MONDO:0010150	EFO:0000181
nasopharyngeal carcinoma	3	MONDO:0015459	MONDO:0015459
central nervous system neoplasm	2	MONDO:0006130	EFO:1000158
hypopharyngeal carcinoma	2	MONDO:0005216	EFO:0002938

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 42.

Phase distribution

Phase	Trials
PHASE2	24
PHASE3	9
PHASE1/PHASE2	5
PHASE1	2
PHASE4	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02088515	PHASE4	COMPLETED	Nedaplatin (Jiebaishu®) Combined With Docetaxel for Advanced Lung Squamous Cell Carcinoma
NCT03503136	PHASE3	NOT_YET_RECRUITING	Nedaplatin Versus Cisplatin and Capecitabine Versus Fluorouracil in IC + CCRT for Locoregionally Advanced NPC
NCT04437329	PHASE3	RECRUITING	Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma
NCT06102395	PHASE3	RECRUITING	Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC
NCT01479504	PHASE3	UNKNOWN	A Multicenter Trial Evaluating the Efficacy of Nedaplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
NCT01540136	PHASE3	COMPLETED	Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Nasopharyngeal Carcinoma
NCT02301208	PHASE3	UNKNOWN	Weekly Cisplatin or Nedaplatin Concurrent With Intensity-modulated Radiation Therapy in Nasopharyngeal Carcinoma
NCT02537925	PHASE3	UNKNOWN	The Effect of COX-2 Inhibitor on Radiosensitivity in Nasopharyngeal Carcinoma
NCT02607592	PHASE3	UNKNOWN	A Prospective Multi-center Phase III Randomized Controlled Trial
NCT02643407	PHASE3	UNKNOWN	Nedaplatin/Docetaxel Versus Cisplatin/Docetaxel in Treatment of Advanced/Relapsed Squamous Cell Lung Cancer
NCT05039606	PHASE2	NOT_YET_RECRUITING	Clinical Study of Radiotherapy Combined With Nedaplatin Contrast and Cisplatin for the Treatment of Locally Advanced Head and Neck Squamous Carcinoma
NCT05515315	PHASE2	RECRUITING	Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma
NCT06010212	PHASE1/PHASE2	NOT_YET_RECRUITING	Fruquintinib as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma
NCT06508229	PHASE2	NOT_YET_RECRUITING	Adebrelimab Combined With Albumin Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable ESCC
NCT06953323	PHASE1/PHASE2	RECRUITING	A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors
NCT07019181	PHASE2	NOT_YET_RECRUITING	Tislelizumab Combined With Chemotherapy for the Perioperative Treatment of Esophageal Squamous Carcinoma
NCT07046221	PHASE2	NOT_YET_RECRUITING	Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery
NCT07284836	PHASE2	RECRUITING	Phase II Trial of Albumin-Bound Paclitaxel Combined With Nedaplatin (TP) Via Hepatic Arterial Infusion for Advanced Breast Cancer Patients With Liver Metastases After Failure of Standard Therapy
NCT07374003	PHASE2	ACTIVE_NOT_RECRUITING	Ipromlimab and Tuvonralimab Combined With Albumin-Bound Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
NCT01265147	PHASE2	UNKNOWN	Intensity-modulated Radiation Therapy Combined With Cisplatin or Nedaplatin Chemotherapy in Nasopharyngeal Carcinoma
NCT01694576	PHASE2	TERMINATED	NPC Staged N2-3M0:Adjuvant Chemotherapy or Just Observation After Concurrent Chemoradiation
NCT01712919	PHASE1/PHASE2	COMPLETED	Chemoradiation Plus Weekly c225 Against Locoregionally Advanced Nasopharyngeal Carcinoma (NPC)
NCT01735747	PHASE2	UNKNOWN	Temozolomide, Nedaplatin, Vincristine, and Radiotherapy as First-line Treatment in Newly Diagnosed Primary CNS Lymphoma
NCT02350517	PHASE2	COMPLETED	Endostar Combined With Paclitaxel and Nedaplatin in Treating Patients With Recurrent or Metastatic Esophageal Cancer
NCT02429622	PHASE1/PHASE2	COMPLETED	Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy for Locally Advanced Esophageal Carcinoma
NCT02590133	PHASE2	UNKNOWN	A Phase II Clinical Trial of Chemotherapy With or Without Endostar® Continuous Intravenous Infusion in Refractory NPC
NCT02776163	PHASE2	COMPLETED	Postoperative Concurrent Chemoradiotherapy in Treating Patients With High-Risk Salivary Gland Carcinomas
NCT02789189	PHASE2	TERMINATED	Nedaplatin Combined With Gemcitabine in the Treatment of Recurrent and/or Metastatic Nasopharyngeal Carcinoma : a Single Arm and Phase Ⅱ Clinical Trail
NCT02835404	PHASE2	UNKNOWN	Pelvic External Combined With 252-Cf Neutron Intracavitary Radiotherapy With or Without Platinum in Treating Advanced Cervical Cancer
NCT02858206	PHASE2	UNKNOWN	Simultaneous Integrated Boost Radiotherapy and Concurrent Nimotuzumab or Chemotherapy for Esophageal Carcinoma
NCT02861690	PHASE2	COMPLETED	Liposomal Paclitaxel Combined Nedaplatin in Treatment of Advanced or Recurrent Esophageal Carcinoma
NCT03603756	PHASE2	UNKNOWN	SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer
NCT03649945	PHASE2	UNKNOWN	Endostatin Combined With Chemotherapy for Adjuvant Treatment of Esophageal Cancer
NCT03917966	PHASE2	UNKNOWN	The Phase II Trial of SHR-1210 Combined With Preoperative Chemotherapy or Apatinib for Locally Advanced ESCC
NCT04834206	PHASE2	COMPLETED	Nedaplatin in Treatment for Nasopharyngeal Carcinoma
NCT04844385	PHASE2	UNKNOWN	Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
NCT04888403	PHASE2	UNKNOWN	Exploring the Safety and Effectiveness of Toripalimab Combined With Neoadjuvant Radiotherapy and Chemotherapy in the Locally Advanced Esophageal Squamous Cell Carcinoma
NCT05777707	PHASE1/PHASE2	UNKNOWN	Neoadjuvant Therapy of PD-1 Blockade Combined With Chemotherapy for Esophageal Carcinoma
NCT06170697	PHASE2	UNKNOWN	Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma
NCT01175460	PHASE1	COMPLETED	S-1 Plus Nedaplatin With Concurrent Radiotherapy for Advanced Esophageal Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).